Pharmaceutical composition containing prasugrel and carbazochrome sodium sulfonate

A technology of sodium carbosulfonate and its composition, which is applied in the field of new pharmaceutical compositions, can solve problems such as reducing patient compliance and rebounding of cardiovascular events, and achieve the effect of inhibiting platelet aggregation

Active Publication Date: 2009-10-14
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

If the drug induces an increased risk of bleeding, even if the bleeding is not severe, it will significantly reduce the patient'

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing prasugrel and carbazochrome sodium sulfonate
  • Pharmaceutical composition containing prasugrel and carbazochrome sodium sulfonate
  • Pharmaceutical composition containing prasugrel and carbazochrome sodium sulfonate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Embodiment 1 common tablet

[0015] Sodium carbosulfonate 50g

[0016] Prasugrel Maleate 5g

[0017] Microcrystalline Cellulose 250g

[0018] Lactose 20g

[0019] 10% starch slurry appropriate amount

[0020] Magnesium stearate 0.8g

[0021] Preparation process: Weigh the prescribed amount of sodium carbosulfonate, prasugrel maleate, microcrystalline cellulose, and lactose and mix evenly. In addition, add an appropriate amount of 10% starch slurry to the mixed powder, mix evenly, make soft materials, pass through a 18-mesh nylon sieve to make wet granules, and dry at about 60°C. The moisture content of dry granules should be controlled below 1.5%. Sieve through a 20-mesh sieve, mix with magnesium stearate, and press into tablets.

Embodiment 2

[0022] Embodiment 2 common tablet

[0023] Sodium carbosulfonate 10g

[0024] Prasugrel HCl 20g

[0025] Starch 140g

[0026] Dextrin 120g

[0027] 50% ethanol appropriate amount

[0028] Magnesium Stearate 1.0g

[0029] Preparation process: Weigh the prescription amount of sodium carbosulfonate, prasugrel hydrochloride, starch and dextrin and mix evenly. In addition, an appropriate amount of 50% ethanol is added to the mixed powder, mixed evenly, made into soft material, passed through a 18-mesh nylon sieve to make wet granules, dried at about 60°C, and the moisture content of the dry granules should be controlled below 1.5%. Sieve through a 20-mesh sieve, mix with magnesium stearate, and press into tablets.

Embodiment 3

[0030] Embodiment 3 Dispersible tablets

[0031] Sodium carbosulfonate 5g

[0032] Prasugrel 25g

[0033] Croscarmellose Sodium 10g

[0034] Microcrystalline Cellulose 150g

[0035] Polyvinylpyrrolidone 5.5g

[0036] 5% PVP 60% ethanol solution appropriate amount

[0037] Micronized silica gel 5g

[0038]Preparation process: Weigh carbosulfonate sodium and prasugrel according to the prescription, use microcrystalline cellulose as filler, cross-linked carmellose sodium and polyvinylpyrrolidone as disintegrants, 5% PVP 60% alcohol solution It is used as binder, and micronized silica gel is used as flow aid. It is granulated in one step in a fluidized bed, and then compressed into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition containing active carbazochrome sodium sulfonate and prasugrel or the pharmacologically acceptable salt thereof. The invention aims to invent a more effective and low adverse-reaction method for curing thrombotic diseases by using the combined medication of the carbazochrome sodium sulfonate and the prasugrel. After conscientious trail of the patent applicant for many times, the effect of applying the carbazochrome sodium sulfonate to inhibit thrombosis in a combined manner is discovered unexpected in the process of applying the prasugrel to cure the thrombotic diseases, the anticoagulant effect of the prasugrel is not abated but increased, and the very good synergistic effects are achieved after the combination of the carbazochrome sodium sulfonate and the prasugrel, therefore, the risk of bleeding is greatly reduced when the advantages of good anticoagulant activity and fast effect of the prasugrel during the antiplatelet aggregation are fully exerted, the risk of bleeding caused by the prasugrel is effectively reduced and the compliance of patients is enhanced.

Description

technical field [0001] The invention belongs to a new pharmaceutical composition, in particular to a pharmaceutical composition comprising prasugrel or a pharmacologically acceptable salt thereof and sodium carbosulfonate as active ingredients. Background technique [0002] Sodium carbosulfonate (Xinanluoxue) is a new generation of vascular hemostatic drug. It is a derivative of Anluoxue. The sodium sulfonate group is introduced into the molecular structure to overcome the low solubility of Anluoxue. It must be prepared by salicylic acid. Disadvantages of solubilization, and avoid the salicylic acid reaction that may occur after long-term repeated application. Compared with Anluoxue (adrenochrome hydrazone), sodium carbosulfonate has high water solubility, multiple routes of administration (oral, intramuscular or intravenous injection, intravenous infusion, endoscopic spraying, etc.), and has a fast hemostatic effect. Less adverse reactions, wide range of application, etc.,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4365A61K31/404A61P7/02
Inventor 赵志全姚景春
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap